Show simple item record

dc.contributor.advisorSchaay, Nikki
dc.contributor.authorSerag, Hani
dc.date.accessioned2018-06-20T10:32:40Z
dc.date.available2018-08-31T22:10:06Z
dc.date.issued2014
dc.identifier.urihttp://hdl.handle.net/11394/6070
dc.descriptionMagister Public Health - MPH (Public Health)
dc.description.abstractEgypt has the highest burden of Hepatitis C Viral infection (HCV) in the world with 10% between 15- 60 years old having HCV antibodies and 7% having chronic HCV infection. HCV is more concentrated among rural, aged, less educated, and poor population groups in addition to patients who require frequent blood transfusion or on renal dialysis, and injection drug users. Despite advancement in antiviral treatments with higher than 90% sustained virologic response (efficacy), access remains limited. The government strategy tied expanding the access to antiviral treatment to a price reduction through subsidies, but an expansion of HCV treatment coverage was not observed. This suggests a broader range of barriers in addition to the financial affordability.
dc.language.isoen
dc.publisherUniversity of Western Cape
dc.titleBarriers to accessibility to antiviral treatment for patients with Chronic Viral Hepatitis C in Egypt
dc.rights.holderUniversity of Western Cape


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record